Related Experiment Video
Updated: Nov 6, 2025

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
Published on: February 16, 2016
A nephroprotective iodinated contrast agent with cardioprotective properties: A pilot study
Elizabeth S Rowe1, Vernon D Rowe1, John Hunter1
1Neurrow Pharmaceuticals, Inc, Shawnee, Kansas, USA.
Sulfobutylether beta cyclodextrin (SBECD)-iohexol demonstrates cardioprotective effects, preserving cardiomyocyte integrity and myocardial function during ischemia. This novel contrast agent shows superiority over iohexol alone in preventing cardiac injury.
Area of Science:
- Cardiovascular Research
- Radiology and Imaging
- Nephrology
Background:
- Iodinated X-ray contrast agents are essential for visualizing heart and brain vasculature in acute ischemic syndromes.
- These agents can cause kidney and organ injury; sulfobutylether beta cyclodextrin (SBECD)-iohexol is under investigation for renal safety.
- Preclinical studies indicated SBECD-iohexol mitigates contrast-induced acute kidney injury by inhibiting apoptosis.
Purpose of the Study:
- To evaluate the cardioprotective potential of SBECD-iohexol compared to iohexol alone.
- To assess the impact of SBECD-iohexol on myocardial function and integrity in a rat ischemia-reperfusion model.
Main Methods:
- A male rat model of myocardial ischemia-reperfusion was employed, involving 30 minutes of coronary artery ligation followed by 2 hours of reperfusion.
- Rats were intravenously injected with vehicle, iohexol, SBECD, or SBECD-iohexol prior to ischemia.
- Measurements included infarct size, hemodynamic parameters, and serum cardiac markers.
Main Results:
- SBECD-iohexol administration prevented the significant increase in serum creatine kinase observed with iohexol alone.
- Hemodynamic parameters, including mean arterial pressure and rate pressure product, were preserved in the SBECD-iohexol group.
- No significant differences in infarct size or serum creatinine were detected among the groups.
Conclusions:
- SBECD-iohexol demonstrates superior efficacy compared to iohexol alone in preserving cardiomyocyte integrity.
- The study suggests SBECD-iohexol effectively preserves myocardial function during ischemic events.
- These findings support SBECD-iohexol as a potentially safer and more effective contrast agent for cardiovascular procedures.
More Related Videos
Related Concept Videos
Imaging Studies for Cardiovascular System V: CT
Radiological Investigation I: X-ray and CT
Imaging Studies VII: Vascular Imaging
Imaging Studies for Cardiovascular System IV: CMRI
Imaging Studies III: Computed Tomography
Acute Kidney Injury IV: Diagnostic Studies and Prevention

